Plant Name: Chaetomorpha moniligera
Taxonomic Information:
Plant ID: NPO336
Plant Latin Name: Chaetomorpha moniligera
Taxonomy Genus: Chaetomorpha
Taxonomy Family: Cladophoraceae
Plant External Links:
NCBI TaxonomyDB:
3186
Plant-of-the-World-Online:
n.a.
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| DRD1; DRD2; | |
| BCHE; ACHE; | |
| MTOR; PKM; ALOX15; | |
| NFKB1; STAT6; HIF1A; TP53; | |
| HTT; THPO; LMNA; | |
| SMN1;SMN2; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | MTOR | Serine/threonine-protein kinase mTOR | P42345 | CHEMBL2842 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Hydrolase | BCHE | Butyrylcholinesterase | P06276 | CHEMBL1914 |
| Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
| Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
| Small molecule receptor (family A GPCR) | DRD1 | Dopamine D1 receptor | P21728 | CHEMBL2056 |
| Small molecule receptor (family A GPCR) | DRD2 | Dopamine D2 receptor | P14416 | CHEMBL217 |
| Transcription Factor | NFKB1 | Nuclear factor NF-kappa-B p105 subunit | P19838 | CHEMBL3251 |
| Transcription Factor | STAT6 | Signal transducer and activator of transcription 6 | P42226 | CHEMBL5401 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transcription Factor | TP53 | Cellular tumor antigen p53 | P04637 | CHEMBL4096 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.252E-11 | 2.725E-07 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 9.469E-08 | 2.968E-04 | BCHE, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.212E-07 | 2.968E-04 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0005488; binding | GO:0042802; identical protein binding | 1.227E-07 | 2.968E-04 | ACHE, BCHE, DRD2, HTT, MTOR, NFKB1, PKM, SMN1, SMN2, STAT6, TP53 |
| BP | GO:0007610; behavior | GO:0008542; visual learning | 1.579E-07 | 3.092E-04 | DRD1, DRD2, HIF1A, MTOR |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.076E-07 | 3.092E-04 | CYP1A2, CYP2C19, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.076E-07 | 3.092E-04 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0023052; signaling | GO:0050805; negative regulation of synaptic transmission | 5.102E-07 | 4.862E-04 | ACHE, BCHE, DRD1, DRD2 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 5.136E-07 | 4.862E-04 | ALOX15, CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0003990; acetylcholinesterase activity | 1.019E-06 | 7.154E-04 | ACHE, BCHE |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 1.659E-06 | 1.129E-03 | CYP1A2, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 3.054E-06 | 1.633E-03 | CYP2D6, CYP3A4 |
| BP | GO:0009987; cellular process | GO:0071456; cellular response to hypoxia | 3.595E-06 | 1.779E-03 | HIF1A, LMNA, MTOR, TP53 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 5.565E-06 | 2.376E-03 | CYP2C19, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 6.104E-06 | 2.416E-03 | CYP1A2, CYP3A4 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.209E-06 | 2.883E-03 | CYP1A2, CYP2C19, CYP2D6, CYP3A4 |
| BP | Unclassified; | GO:0021853; cerebral cortex GABAergic interneuron migration | 1.017E-05 | 3.354E-03 | DRD1, DRD2 |
| BP | GO:0008152; metabolic process | GO:0046483; heterocycle metabolic process | 1.605E-05 | 4.723E-03 | ACHE, BCHE, CYP1A2, CYP2C19, CYP2D6, CYP3A4, HIF1A, MTOR, NFKB1, PKM, SMN1, SMN2, STAT6, TP53 |
| BP | GO:0008152; metabolic process | GO:0006725; cellular aromatic compound metabolic process | 1.776E-05 | 4.896E-03 | ACHE, BCHE, CYP1A2, CYP2D6, DRD1, DRD2, HIF1A, MTOR, NFKB1, PKM, SMN1, SMN2, STAT6, TP53 |
| BP | GO:0023052; signaling | GO:0051584; regulation of dopamine uptake involved in synaptic transmission | 2.841E-05 | 7.279E-03 | DRD1, DRD2 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 4.013E-05 | 9.395E-03 | DRD1, DRD2, HIF1A, HTT, MTOR, PKM, SMN1, SMN2 |
| BP | GO:0050896; response to stimulus | GO:0007584; response to nutrient | 4.130E-05 | 9.566E-03 | BCHE, MTOR, PKM, TP53 |
| BP | GO:0050896; response to stimulus | GO:0071417; cellular response to organonitrogen compound | 4.196E-05 | 9.617E-03 | DRD1, MTOR, NFKB1, PKM, TP53 |
| CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 6.681E-05 | 1.311E-02 | SMN1, SMN2 |
| CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 7.890E-05 | 1.420E-02 | SMN1, SMN2 |
| CC | GO:0016020; membrane | GO:0031090; organelle membrane | 1.419E-04 | 2.208E-02 | CYP1A2, CYP2C19, CYP2D6, CYP3A4, DRD1, DRD2, HTT, LMNA, MTOR, STAT6 |
| CC | GO:0044464; cell part | GO:0034719; SMN-Sm protein complex | 1.543E-04 | 2.301E-02 | SMN1, SMN2 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.699E-08 | 1.937E-06 | CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05230 | Central carbon metabolism in cancer | 5.352E-07 | 2.291E-05 | PKM, TP53, HIF1A, MTOR |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 6.028E-07 | 2.291E-05 | CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
| 09160 Human Diseases | 09164 Substance dependence | hsa05030 | Cocaine addiction | 1.530E-05 | 4.360E-04 | DRD1, DRD2, NFKB1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 5.086E-05 | 1.160E-03 | CYP2D6, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05215 | Prostate cancer | 9.193E-05 | 1.497E-03 | TP53, NFKB1, MTOR |
| 09150 Organismal Systems | 09149 Aging | hsa04211 | Longevity regulating pathway - mammal | 1.082E-04 | 1.541E-03 | TP53, NFKB1, MTOR |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 7.201E-05 | 1.368E-03 | CYP1A2, CYP3A4, CYP2C19 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04066 | HIF-1 signaling pathway | 1.419E-04 | 1.797E-03 | HIF1A, NFKB1, MTOR |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 1.818E-04 | 2.073E-03 | CYP2D6, ALOX15, CYP2C19 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04919 | Thyroid hormone signaling pathway | 2.121E-04 | 2.198E-03 | TP53, HIF1A, MTOR |
| 09140 Cellular Processes | 09143 Cell growth and death | hsa04210 | Apoptosis | 3.507E-04 | 3.332E-03 | LMNA, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05200 | Pathways in cancer | 5.758E-04 | 4.376E-03 | HIF1A, TP53, NFKB1, MTOR |
| 09160 Human Diseases | 09167 Infectious diseases | hsa05161 | Hepatitis B | 3.966E-04 | 3.478E-03 | STAT6, TP53, NFKB1 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04630 | Jak-STAT signaling pathway | 4.996E-04 | 4.068E-03 | THPO, STAT6, MTOR |
| 09160 Human Diseases | 09161 Cancers | hsa05205 | Proteoglycans in cancer | 1.034E-03 | 6.382E-03 | TP53, HIF1A, MTOR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 9.763E-04 | 6.382E-03 | DRD1, DRD2, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05203 | Viral carcinogenesis | 1.064E-03 | 6.382E-03 | PKM, TP53, NFKB1 |
| 09160 Human Diseases | 09161 Cancers | hsa05221 | Acute myeloid leukemia | 1.467E-03 | 8.244E-03 | NFKB1, MTOR |
| 09160 Human Diseases | 09166 Endocrine and metabolic diseases | hsa04930 | Type II diabetes mellitus | 1.042E-03 | 6.382E-03 | PKM, MTOR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04150 | mTOR signaling pathway | 1.624E-03 | 8.280E-03 | HIF1A, MTOR |
| 09160 Human Diseases | 09161 Cancers | hsa05214 | Glioma | 1.903E-03 | 8.280E-03 | TP53, MTOR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.733E-03 | 8.280E-03 | ALOX15, CYP2C19 |
| 09160 Human Diseases | 09161 Cancers | hsa05212 | Pancreatic cancer | 1.961E-03 | 8.280E-03 | TP53, NFKB1 |
| 09160 Human Diseases | 09162 Immune diseases | hsa05321 | Inflammatory bowel disease (IBD) | 1.903E-03 | 8.280E-03 | STAT6, NFKB1 |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.519E-03 | 8.244E-03 | CYP1A2, CYP3A4 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.903E-03 | 8.280E-03 | CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05220 | Chronic myeloid leukemia | 2.393E-03 | 9.406E-03 | TP53, NFKB1 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04920 | Adipocytokine signaling pathway | 2.203E-03 | 8.968E-03 | NFKB1, MTOR |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cocaine addiction | F14.2 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Advanced stage Parkinson's disease | F02.3, G20 | DRD2; |
| K00-K95: Diseases of the digestive system | Dermal necrosis | K05 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Depressive fatigue | R53.82 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Dementia | F01-F07 | DRD1; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ACHE; |
| C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | DRD2; |
| NA: NA | Itching | NA | DRD2; |
| J00-J99: Diseases of the respiratory system | Bronchitis | J20-J21, J42 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Carcinoid syndrome | E34.0 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | DRD1; DRD2; |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | DRD2; |
| NA: NA | Inflammatory diseases | NA | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; DRD2; |
| K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiac failure | I50 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cardiotonic | I50 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | CYP2D6; |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine headaches | G43 | DRD2; |
| J00-J99: Diseases of the respiratory system | Nasal congestion | J34.89 | DRD2; |
| NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
| NA: NA | Malignant essential hypertension | NA | DRD2; |
| NA: NA | Malignant phaeochromocytoma | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Excessive bleeding following childbirth and spontaneous or elective abortion | O04 | DRD1; |
| I00-I99: Diseases of the circulatory system | Maintain blood pressure in hypotensive states | I10 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | CYP2D6; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | DRD1; DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Emesis | R11 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | ACHE; |
| H00-H59: Diseases of the eye and adnexa | Ophthalmic disease | H00-H59 | DRD2; |
| C00-D49: Neoplasms | Breast cancer | C50 | DRD2; |
| NA: NA | False perceptions | NA | DRD2; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypotension | I95 | DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ACHE; DRD1; DRD2; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; DRD1; DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
| K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
| NA: NA | Schizoaffective disorders | NA | DRD2; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Idiopathic thrombocytopenic purpura | D69.3 | DRD2; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | DRD1; DRD2; |
| NA: NA | Peripheral vasoconstriction | NA | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6; DRD2; |
| O00-O9A: Pregnancy, childbirth and the puerperium | Postpartum haemorrhage | O72 | DRD2; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Nausea | R11 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Sexual dysfunction | F52 | DRD2; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
| NA: NA | Benign prostatic hypertrophy | NA | DRD2; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Fibrosis | L90.5 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | DRD1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychosis | F20-F29 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychotic disorders | F20-F29 | DRD1; DRD2; |
| NA: NA | Vomiting | NA | DRD2; |
| NA: NA | Corneal vascularity | NA | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Acromegaly | E22.0 | DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | DRD1; |
| A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | DRD2; |
| N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
| NA: NA | Upper abdominal bloating | NA | ACHE; |
| I00-I99: Diseases of the circulatory system | Pulmonary hypertension | I27.0, I27.2 | DRD2; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | DRD2; |
| A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
| NA: NA | Hyperaemia | NA | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | DRD2; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | DRD2; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; DRD2; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperprolactinemia | E22.1 | DRD2; |
| H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | DRD2; |
| K00-K95: Diseases of the digestive system | Gastrointestinal problems | K30-K31, Q40-Q41 | DRD2; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
